NACP money mostly goes toward blood safety, HIV testing and counselling, condom distribution and treating sexually transmitted infections. None of that money is meant for other disease programmes directly, but some programmes still gain from it because the same patients and the same health system touch both diseases.
- RCH Programme: This covers reproductive and child health broadly. HIV testing in antenatal clinics helps here, but it is not the strongest secondary link.
- MCH services: Similar overlap with mother and child care, but again this is not where NACP's biggest side benefit lands.
- Immunization Programme: Vaccine preventable disease control does not share much operational overlap with HIV services.
- National Tuberculosis Control Programme: Tuberculosis is the leading opportunistic infection in HIV positive people. As NACP builds up counselling centres, labs, and referral networks, the same system ends up finding and managing far more TB cases among people living with HIV, which is a real secondary gain for TB control.
So the closest and most recognized secondary dividend of NACP investment falls on TB control, because of how tightly HIV and TB are linked in the same patients and the same clinics.
Let's summarize:
- NACP funds target HIV specific services directly.
- TB control gains the biggest secondary benefit due to high HIV-TB co-infection and shared health infrastructure.
The correct answer is the National Tuberculosis Control Programme.